JP2023543299A - 化合物及び癌の治療におけるそれらの使用 - Google Patents

化合物及び癌の治療におけるそれらの使用 Download PDF

Info

Publication number
JP2023543299A
JP2023543299A JP2023519522A JP2023519522A JP2023543299A JP 2023543299 A JP2023543299 A JP 2023543299A JP 2023519522 A JP2023519522 A JP 2023519522A JP 2023519522 A JP2023519522 A JP 2023519522A JP 2023543299 A JP2023543299 A JP 2023543299A
Authority
JP
Japan
Prior art keywords
mmol
formula
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023519522A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022069520A5 (https=
JP2023543299A5 (https=
Inventor
ボルイェソン，ウルフ
ウィリアム ダンピア ペリー，マシュー
グレープナー，クリストフ
ニール マイケリーディス，イアコヴォス
ジョージ クリストファー ヘイハウ，トーマス
グラント ケトル，ジェイソン
ウィリアム コリー，ギャビン
イアン ストーラー，ロバート
カウル バガル，シャランジート
ファラン，シャーリーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2023543299A publication Critical patent/JP2023543299A/ja
Publication of JPWO2022069520A5 publication Critical patent/JPWO2022069520A5/ja
Publication of JP2023543299A5 publication Critical patent/JP2023543299A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
JP2023519522A 2020-09-30 2021-09-29 化合物及び癌の治療におけるそれらの使用 Pending JP2023543299A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063085384P 2020-09-30 2020-09-30
US63/085,384 2020-09-30
PCT/EP2021/076752 WO2022069520A1 (en) 2020-09-30 2021-09-29 Compounds and their use in treating cancer

Publications (3)

Publication Number Publication Date
JP2023543299A true JP2023543299A (ja) 2023-10-13
JPWO2022069520A5 JPWO2022069520A5 (https=) 2024-10-07
JP2023543299A5 JP2023543299A5 (https=) 2024-10-07

Family

ID=78085628

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023519522A Pending JP2023543299A (ja) 2020-09-30 2021-09-29 化合物及び癌の治療におけるそれらの使用

Country Status (17)

Country Link
US (1) US20230374007A1 (https=)
EP (1) EP4221756A1 (https=)
JP (1) JP2023543299A (https=)
KR (1) KR20230079408A (https=)
CN (1) CN116249554A (https=)
AU (2) AU2021353968B2 (https=)
BR (1) BR112023005708A2 (https=)
CA (1) CA3195695A1 (https=)
CL (1) CL2023000881A1 (https=)
CO (1) CO2023005188A2 (https=)
CR (1) CR20230185A (https=)
DO (1) DOP2023000062A (https=)
EC (1) ECSP23030959A (https=)
IL (1) IL301626A (https=)
MX (1) MX2023003564A (https=)
PE (1) PE20230782A1 (https=)
WO (1) WO2022069520A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115141179B (zh) * 2021-03-31 2024-09-13 江苏恒瑞医药股份有限公司 一种新型苯并杂环基类衍生物、其制备方法及其在医药上的应用
CN119301111A (zh) 2022-03-24 2025-01-10 葛兰素史密斯克莱知识产权发展有限公司 作为protac中的降解决定子的2,4-二氧代四氢嘧啶基衍生物
USD1018676S1 (en) * 2022-04-15 2024-03-19 Puttshack LTD Miniature golf hole
USD1018746S1 (en) * 2022-04-15 2024-03-19 Puttshack LTD Miniature golf hole
USD1020957S1 (en) * 2022-04-15 2024-04-02 Puttshack LTD Miniature golf hole
USD1018747S1 (en) * 2022-04-15 2024-03-19 Puttshack LTD Miniature golf hole
CN119855812A (zh) * 2022-09-14 2025-04-18 海南先声再明医药股份有限公司 多并环类化合物及其用途
US20240374588A1 (en) 2023-04-07 2024-11-14 Astrazeneca Ab Irak4 protacs
TW202515566A (zh) 2023-06-14 2025-04-16 瑞典商阿斯特捷利康公司 Ｓｍａｒｃａ２降解劑及其用途
MX2025015084A (es) * 2023-06-14 2026-02-03 Astrazeneca Ab Degradadores de smarca2 y usos de estos
WO2025036489A1 (zh) * 2023-08-17 2025-02-20 海思科医药集团股份有限公司 一种氰基芳香环衍生物及其在医药上的应用
IL326555A (en) 2023-09-22 2026-04-01 Glaxosmithkline Ip Dev Ltd Androgen receptor protax
CN117430605A (zh) * 2023-10-26 2024-01-23 广西天铭药业有限公司 一种kras g12c抑制剂amg-510中间体的合成方法
US20250177539A1 (en) * 2023-12-01 2025-06-05 Astrazeneca Ab Er degraders and uses thereof
WO2025125575A1 (en) 2023-12-14 2025-06-19 Astrazeneca Ab Irak4 protacs

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502097A (ja) * 2014-12-23 2018-01-25 ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
WO2019140387A1 (en) * 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
JP2020506922A (ja) * 2017-01-31 2020-03-05 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． セレブロンリガンド、およびセレブロンリガンドを含有する二官能性化合物
WO2020132561A1 (en) * 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0422263D0 (en) 2004-10-07 2004-11-10 Glaxo Group Ltd Novel compounds
PH12012502079A1 (en) 2010-04-16 2013-02-11 Ac Immune Sa Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
JP6509838B2 (ja) 2013-06-26 2019-05-08 アッヴィ・インコーポレイテッド Ｂｔｋ阻害薬としての一級カルボキサミド類
ES2826443T3 (es) 2014-09-25 2021-05-18 Araxes Pharma Llc Inhibidores de proteínas mutantes KRAS G12C
WO2019057757A1 (en) * 2017-09-20 2019-03-28 Astrazeneca Ab 1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502097A (ja) * 2014-12-23 2018-01-25 ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
JP2020506922A (ja) * 2017-01-31 2020-03-05 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． セレブロンリガンド、およびセレブロンリガンドを含有する二官能性化合物
WO2019140387A1 (en) * 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
WO2020132561A1 (en) * 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation

Also Published As

Publication number Publication date
WO2022069520A1 (en) 2022-04-07
US20230374007A1 (en) 2023-11-23
CL2023000881A1 (es) 2023-11-17
AU2021353968A9 (en) 2024-10-03
AU2025200137A1 (en) 2025-01-30
EP4221756A1 (en) 2023-08-09
AU2021353968A1 (en) 2023-06-08
MX2023003564A (es) 2023-04-04
CO2023005188A2 (es) 2023-05-19
AU2021353968B2 (en) 2024-10-10
KR20230079408A (ko) 2023-06-07
PE20230782A1 (es) 2023-05-09
DOP2023000062A (es) 2023-05-31
ECSP23030959A (es) 2023-05-31
CN116249554A (zh) 2023-06-09
CR20230185A (es) 2023-06-27
CA3195695A1 (en) 2022-04-07
BR112023005708A2 (pt) 2023-05-02
IL301626A (en) 2023-05-01

Similar Documents

Publication Publication Date Title
JP2023543299A (ja) 化合物及び癌の治療におけるそれらの使用
JP7086395B2 (ja) 置換インドールＭｃｌ－１阻害剤
CN102391255B (zh) 作为β3肾上腺素能受体激动剂的羟甲基吡咯烷
ES2551592T3 (es) Pirazolo[1,5-a]piridinas como inhibidores de TRK
JP6321045B2 (ja) キナーゼ阻害剤としての複素環式アミド
AU2016264958B2 (en) Benzoimidazole derivatives as PAD4 inhibitors
AU2015289897B2 (en) Spirocycloheptanes as inhibitors of rock
AU2014304046B2 (en) Benzimidazolyl-methyl urea derivatives as ALX receptor agonists
ES2494718T3 (es) Derivados de tetrahidro-pirido-pirimidina
JP2022538192A (ja) Ｉｒａｋ分解剤およびその使用
TW202216679A (zh) 抗病毒化合物
ES2956090T3 (es) Inhibidores de bencimidazol de enzimas PAD
CN121889399A (zh) Kras蛋白水解靶向嵌合体
KR20190012167A (ko) 이소퀴놀린-3-일 카르복스아마이드 및 이의 제제와 용도
US8648074B2 (en) Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers
JP2020500909A (ja) ＰＩ３Ｋδ阻害剤としてのイミダゾ［１，５−ａ］ピラジン誘導体
TW202417458A (zh) 調節her2的化合物及方法
ES2887674T3 (es) 1-Arilnaftiridin-3-carboxamidas 7-sustituidas y su uso
CA2797019C (en) Modulators of 5-ht receptors and methods of use thereof
WO2023233033A1 (en) Novel par-2 inhibitors
TW202214634A (zh) 雜環化合物及其衍生物
TW202425999A (zh) 酶抑制劑
CA3236550A1 (en) Spirotricycle ripk1 inhibitors and methods of uses thereof
IL325136A (en) Pyrazolo-pyrimidinone compounds for use in methods for inhibiting kinase week1 a
KR20220052934A (ko) 치환 1,3-페닐 헤테로아릴 유도체 및 질환 치료에서의 이의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240926

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250916

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260313